<DOC>
	<DOCNO>NCT02962297</DOCNO>
	<brief_summary>VENS multicenter , randomize , double-masked , placebo parallel control trial evaluate efficacy safety treatment vitamin E softgel non diabetic adult NASH compare treatment placebo China .</brief_summary>
	<brief_title>Vitamin E Versus Placebo Treatment Non Diabetic Patients With Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>1 . Age : 18 75 , limitation ethnic gender 2 . Body Mass Index ( BMI ) &lt; 35 kg/m2 3 . Patients nonalcoholic steatohepatitis ( NASH ) base liver biopsy obtain within 6 month randomization . The histological evidence NASH define Non alcoholic fatty liver disease activity score（NAS）≥ 4 ( accord Nonalcoholic Steatohepatitis Clinical Research Network , NASH CRN ) minimum 1 score steatosis , lobular inflammation , hepatocyte ballooning respectively . 4 . Fibrosis stage 03 accord nonalcoholic steatohepatitis clinical research network（NASH CRN ) . 5 . Without history significant alcohol consumption period 3 month within 5 year ( &lt; 10 g/day female &lt; 20 g/day male ) . 6 . The lab test result meet requirement : ① Alanine aminotransferase （ALT） &lt; 5 time normal upper limit ② Creatinine ( Cr ) &lt; normal upper limit ③ Albumin （ALB） &gt; 3.5g/L ④ International normalize ratio（INR）= 0.81.3 ⑤ Fasting plasma glucose ( FPG ) &lt; 126mg/dL（7mmol/L） and/or 2h postprandial plasma glucose ( PPG ) &lt; 200mg/dL（11.1mmol/L）and/ HbA1C &lt; 6.5 % 7 . If participant hypertension , he/she require stable antihypertensive drug ( ) keep blood pressure stable . ( blood pressure &lt; 140/90 mmHg ) 3 month prior randomization . 8 . If participant use statin fibrate , he/she require stable dose keep lipid stable ( triglyceride ( TG ) &lt; 1.7 mmol/L , total cholesterol ( TC ) &lt; 5.72 mmol/L , LDLc &lt; 3.64 mmol/L ) 3 month prior randomization . 9 . Women childbearing potential : negative pregnancy test screen randomization willingness use effective form birth control trial ( least include one barrier contraceptive method ) breast feed 10 . Men must agree use effective form birth control trial ( least include one barrier contraceptive method ) 11 . All participant need sign inform consent form . 1 . Evidence form acute chronic liver disease . ( Virus hepatitis , Hereditary hemochromatosis , Hepatolenticular degeneration , Alcoholic liver disease , Druginduced hepatopathy ) . 2 . History diabetic mellitus use antidiabetic drug . 3 . Known heart failure New York Heart Association class 2 , 3 , 4 . 4 . Wear cardiac pacemaker . 5 . Hypothyroidism ( TSH &gt; 2 time upper normal limit ) . 6 . History disease affect drug absorption , distribution , metabolism ( inflammatory bowel disease , gastrointestinal surgery , chronic pancreatitis , gluten allergy , vagotomy ) . 7 . Use antiNASH drug within 3 month randomization ( metformin , thiazolidinediones , dipeptidyl peptidase4 ( DPP4 ) inhibitor , glucagonlike peptide1 ( GLP1 ) , sodium glucose contransporter2 ( SGLT2 ) , Sadenosylmethionine e ( SAMe ) , polyene phosphatidyl choline , glycyrrhizin , bicyclol , reduce glutathione , betaine , fish oil , silymarin , oberbic acid/ursodeoxycholic acid ( OCA/UDCA ) , phosphodiesterase ( PDE ) inhibitor , gemfibrozil , vitamin E , long term antibiotic ( &gt; 1 week ) . 8 . Positivity antibody Human Immunodeficiency Virus . 9 . Inability safely obtain liver biopsy . 10 . Known intolerance vitamin E 11 . Inability fill diary card , manage diet exercise , poor compliance . 12 . Dependence abuse alcohol and/or drug . 13 . Any condition opinion investigator would impede compliance hinder completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Vitamin E , Non Diabetic</keyword>
</DOC>